Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro
El-Naggar, S., El-Bolkiny, Y., Ibrahim, F. (2022). Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro. EKB Journal Management System, 6(2), 23-29. doi: 10.21608/jcbr.2022.96763.1233
Sabry A. El-Naggar; Yousry El-Bolkiny; Fatheya Makboul Ibrahim. "Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro". EKB Journal Management System, 6, 2, 2022, 23-29. doi: 10.21608/jcbr.2022.96763.1233
El-Naggar, S., El-Bolkiny, Y., Ibrahim, F. (2022). 'Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro', EKB Journal Management System, 6(2), pp. 23-29. doi: 10.21608/jcbr.2022.96763.1233
El-Naggar, S., El-Bolkiny, Y., Ibrahim, F. Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro. EKB Journal Management System, 2022; 6(2): 23-29. doi: 10.21608/jcbr.2022.96763.1233

Ethylenediamine tetra acetic acid (EDTA) enhances the antitumor efficacy of cisplatin against human breast cancer cells in vitro

Egyptian Journal of Cancer and Biomedical Research
Article 3, Volume 6, Issue 2, June 2022, Page 23-29  XML PDF (1013.08 K)
Document Type: Original Article
DOI: 10.21608/jcbr.2022.96763.1233
View on SCiNiTO View on SCiNiTO
Authors
Sabry A. El-Naggarorcid 1; Yousry El-Bolkiny email orcid 2; Fatheya Makboul Ibrahimorcid 3
1Zoology Department, Faculty of Science, Tanta University, Tanta 3111, Egypt
2Department of Zoology, Faculty of Science, Tanta University, Egypt
3Zoology, Faculty of Science,Suez canal University
Abstract
Background: Ethylenediamine tetra acetic acid (EDTA) is used in several biomedical applications. Aim: The aim of this study was to investigate the effect of EDTA treatment on anticancer efficacy of cisplatin (Cis) against human breast cancer (MCF-7) cells in vitro. Materials and Methods:MCF-7 cells were treated either with Cis, EDTA, or their combination for 24h in vitro. The percentages (%) of the inhibitory, and the median inhibitory concentration (IC50) of EDTA were determined by MTT assay. The % of Cis and EDTA on early and late apoptosis, necrosis, and cell cycle of MCF-7 were assessed by flow cytometry. Results: Our data showed slight antitumor effects for EDTA in vitro. However, Cis/EDTA treatment increased the antitumor efficacy of Cis as evidenced by increasing IC50, and the percentage of MCF-7 mortality. Cis/EDTA co-treatment also increased the % of apoptotic and necrotic MCF-7 cells post 24 h of treatment (26.57 and 16.28%, respectively). Furthermore, this co-treatment arrested MCF-7 cell cycle at G0 phase (32.8%) and G2/M phase (30.25%). Conclusion: Co-treatment of EDTA  with Cis increased the anticancer efficacy  of Cis.
Keywords
EDTA; Cisplatin; MCF-7 cells; In vitro; anti-tumor
Statistics
Article View: 148
PDF Download: 188